Discover. Oncology最新文献_第4页

Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer.

IF 2.8 4区医学

Discover. Oncology Pub Date : 2024-12-22 DOI: 10.1007/s12672-024-01674-x

Qi Shen, Kaichen Zhou, Haosen Lu, Jielin Zhang, Qiqing Xu, Chengsi Zhang, Chunhua Yang, Lijun Mao

引用次数: 0

Assessing the causality between pulmonary arterial hypertension and cancer: insights from Mendelian randomization.

IF 2.8 4区医学

Discover. Oncology Pub Date : 2024-12-21 DOI: 10.1007/s12672-024-01727-1

Yang Fu, Xinwang Duan, Wei Zhou

{"title":"Assessing the causality between pulmonary arterial hypertension and cancer: insights from Mendelian randomization.","authors":"Yang Fu, Xinwang Duan, Wei Zhou","doi":"10.1007/s12672-024-01727-1","DOIUrl":"https://doi.org/10.1007/s12672-024-01727-1","url":null,"abstract":"Background: Previous clinical studies have suggested an increased risk of tumor development in patients with pulmonary arterial hypertension (PAH). However, it remains unclear whether there is a causal relationship between PAH and tumor occurrence. This study investigates the causal link between PAH and cancer from a genetic perspective using Mendelian randomization (MR).Method: Genome-wide association study (GWAS) summary data for PAH and various common cancer types were obtained from the GWAS Catalog. Single nucleotide polymorphisms (SNPs) significantly associated with PAH at the genome-wide significance threshold (P < 1 × 10-6) were selected as instrumental variables (IVs). Inverse-variance weighted (IVW) was used as the primary method for MR analysis, with sensitivity analyses including tests for heterogeneity and horizontal pleiotropy.Results: The results from the IVW analysis indicate that genetically proxied PAH is associated with an increased risk of liver cancer [odd ratio (OR) 1.11, 95% confidence interval (CI) 1.01-1.22, P = 0.025), while showing no significant causal relationship with other common types of tumors (thyroid cancer: OR 0.95, 95% CI 0.86-1.06, P = 0.360; lung cancer: OR 0.95, 95% CI 0.90-1.01, P = 0.129; gastric cancer: OR 0.97, 95% CI 0.93-1.02, P = 0.243; colorectal cancer: OR 1.01, 95% CI 0.98-1.05, P = 0.412). Except for the MR analysis examining the causal effect of PAH on lung cancer (P = 0.049), the remaining MR analyses displayed no significant heterogeneity (P > 0.05). Additionally, the MR-Egger intercept test did not find evidence of horizontal pleiotropy (P > 0.05).Conclusion: This study highlights that PAH may serve as a potential risk factor for this liver cancer. Future research should aim to elucidate the biological mechanisms at play and explore the potential for early interventions that could mitigate cancer risk in this vulnerable population.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"15 1","pages":"821"},"PeriodicalIF":2.8,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of gout on colorectal cancer and its survival: a two-sample Mendelian randomization study.

IF 2.8 4区医学

Discover. Oncology Pub Date : 2024-12-21 DOI: 10.1007/s12672-024-01714-6

Li-Qiang Wei, Yi-Bei Song, Dong Lan, Xue-Jing Miao, Chun-Yu Lin, Shu-Ting Yang, Deng-He Liu, Xiao-Jv Chi

{"title":"Impact of gout on colorectal cancer and its survival: a two-sample Mendelian randomization study.","authors":"Li-Qiang Wei, Yi-Bei Song, Dong Lan, Xue-Jing Miao, Chun-Yu Lin, Shu-Ting Yang, Deng-He Liu, Xiao-Jv Chi","doi":"10.1007/s12672-024-01714-6","DOIUrl":"https://doi.org/10.1007/s12672-024-01714-6","url":null,"abstract":"Background: The relationship between gout and colorectal cancer (CRC) remains unclear, emphasizing the need for additional research to clarify the potential cumulative effect of gout on CRC development.Methods: Leveraging a single nucleotide polymorphism-based genome-wide association study, the potential causal correlation between gout and CRC was initially analyzed using Mendelian randomization (MR). Subsequently, our analysis was expanded to include an assessment of patient survival, with the aim of evaluating the potential causal correlation between gout and CRC and the impact of gout on CRC survival outcomes.Results: According to MR findings, a substantial relationship was observed between gout and the incidence of CRC when CRC was used as the outcome (OR = 0.954, 95% CI = 0.915-0.995). These results indicate a negative relationship between gout and the likelihood of developing CRC. In addition, when evaluating the overall survival (OS) or cancer-specific survival (CSS) of patients with CRC as outcomes, gout exhibited a significant relationship with survival. The inverse variance weighting approach demonstrated a progressive enhancement in CRC survival with the cumulative impact of gout (OS: OR = 2.000 × 10-4, 95% CI = 1.560 × 10-7-0.292; CSS: OR = 2.200 × 10-5, 95% CI = 4.660 × 10-9-0.104).Conclusion: As gout accumulates, it exerts an inhibitory influence on CRC, indicating a potential protective effect. This study provides robust evidence that can guide the development of future clinical treatment approaches and research priorities.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"15 1","pages":"819"},"PeriodicalIF":2.8,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.

IF 2.8 4区医学

Discover. Oncology Pub Date : 2024-12-21 DOI: 10.1007/s12672-024-01590-0

Hamed Afkhami, Aref Yarahmadi, Shoroq Bostani, Nahid Yarian, Mahdieh Sadat Haddad, Shima Sadat Lesani, Seyed Soheil Aghaei, Mohammad Reza Zolfaghari

{"title":"Converging frontiers in cancer treatment: the role of nanomaterials, mesenchymal stem cells, and microbial agents-challenges and limitations.","authors":"Hamed Afkhami, Aref Yarahmadi, Shoroq Bostani, Nahid Yarian, Mahdieh Sadat Haddad, Shima Sadat Lesani, Seyed Soheil Aghaei, Mohammad Reza Zolfaghari","doi":"10.1007/s12672-024-01590-0","DOIUrl":"https://doi.org/10.1007/s12672-024-01590-0","url":null,"abstract":"Globally, people widely recognize cancer as one of the most lethal diseases due to its high mortality rates and lack of effective treatment options. Ongoing research into cancer therapies remains a critical area of inquiry, holding significant social relevance. Currently used treatment, such as chemotherapy, radiation, or surgery, often suffers from other problems like damaging side effects, inaccuracy, and the lack of ability to clear tumors. Conventional cancer therapies are usually imprecise and ineffective and usually develop resistance to treatments and cancer recurs. Cancer patients need fresh and innovative treatment that can reduce side effects while maximizing effectiveness. In recent decades several breakthroughs in these, and other areas of medical research, have paved the way for new avenues of fighting cancer including more focused and more effective alternatives. This study reviews exciting possibilities for mesenchymal stem cells (MSCs), nanomaterials, and microbial agents in the modern realm of cancer treatment. Nanoparticles (NPs) have demonstrated surprisingly high potential. They improve drug delivery systems (DDS) significantly, enhance imaging techniques remarkably, and target cancer cells selectively while protecting healthy tissues. MSCs play a double role in tissue repair and are a vehicle for novel cancer treatments such as gene treatments or NPs loaded with therapeutic agents. Additionally, therapies utilizing microbial agents, particularly those involving bacteria, offer an inventive approach to cancer treatment. This review investigates the potential of nanomaterials, MSCs, and microbial agents in addressing the shortcomings of conventional cancer therapies. We will also discuss the challenges and limitations of using these therapeutic approaches.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"15 1","pages":"818"},"PeriodicalIF":2.8,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Geneticsbiologiesingle cell and expression analysis for erectile dysfunction and cervical cancer targets.

IF 2.8 4区医学

Discover. Oncology Pub Date : 2024-12-21 DOI: 10.1007/s12672-024-01726-2

Tengfei Zhao, Yangyang Li, Huixue Liu, Chongxin Tong

{"title":"Geneticsbiologiesingle cell and expression analysis for erectile dysfunction and cervical cancer targets.","authors":"Tengfei Zhao, Yangyang Li, Huixue Liu, Chongxin Tong","doi":"10.1007/s12672-024-01726-2","DOIUrl":"https://doi.org/10.1007/s12672-024-01726-2","url":null,"abstract":"Background: Sexual dysfunction and cervical cancer are genetically and molecularly two complex health problems. Here, we integrate genetic inference and single-cell expression analysis to identify potential genetic targets for sexual dysfunction and cervical cancer, and assess causality of these targets utilizing Mendelian randomization approaches.Methods: We performed a genome-wide association study (GWAS) to identify genetic variants associated with sexual dysfunction and cervical cancer. Next, we examined the cellular landscape of these variation regions based on scRNAseq data.Results: The study identified several genetic variants that are correlated with sexual dysfunction and cervical cancer, respectively, and these differentially expressed in reproductive and cervical cells. Two-Gene Combination Panel Increased expression of the WISP1 gene was detected in cervical cancer tissues. Twas most highly expressed in T cells, and least well- when cells were proliferating.Conclusions: The study integrates genetics with single-cell expression to nominate genetic targets for sexual dysfunction and cervical cancer and establishes causal support from Mendelian randomization approach.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"15 1","pages":"820"},"PeriodicalIF":2.8,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment.

IF 2.8 4区医学

Discover. Oncology Pub Date : 2024-12-20 DOI: 10.1007/s12672-024-01702-w

Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Fatma Pinar Açar, Salih Tünbekici, Gülçin Çelebi, Burçak Karaca

{"title":"Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment.","authors":"Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, Fatma Pinar Açar, Salih Tünbekici, Gülçin Çelebi, Burçak Karaca","doi":"10.1007/s12672-024-01702-w","DOIUrl":"https://doi.org/10.1007/s12672-024-01702-w","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have significantly improved the five-year survival rate for advanced melanoma. However, many patients exhibit resistance to ICI therapy. This study evaluated the efficacy and prognostic factors of anti-PD-1 (Group A) and nivolumab-ipilimumab (Group B) therapy in patients with advanced melanoma who were resistant to prior ICI therapy. We conducted a retrospective analysis of 56 patients with advanced melanoma who had previously shown resistance to ICI therapy. In the Group A (who have previously shown resistance to anti-CTLA-4, n = 28), the objective response rate (ORR) was 42.9%, with a disease control rate (DCR) of 53%. In the Group B (previously shown resistance to anti-PD-1, n = 28), the ORR was 17.9%, and the DCR was 25%. The ORR was lower in two subgroups: patients who showed progression or relapse in the the initial radiological assessment of prior ICI therapy (ORR 10.5%) and patients who had previously received ICI in the adjuvant setting (ORR 8.3%). A Royal Marsden Hospital (RMH) score of 2-3 was a predictor of OS in both groups (Group A: HR 3.789, 95% CI 1.356-10.589, p = 0.011; Group B: HR 4.281, 95% CI 1.490-12.300, p = 0.007) and for PFS in the Group B (HR 3.167, 95% CI 1.062-9.442, p = 0.039). Anti-PD-1 therapy demonstrated efficacy following resistance to anti-CTLA-4, whereas combination ICI therapy showed lower response rates in patients resistant to anti-PD-1. Further studies are needed to confirm the RMH scores and other prognostic markers and to evaluate subgroups with lower efficacy of nivolumab-ipilimumab therapy.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"15 1","pages":"813"},"PeriodicalIF":2.8,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of stored autologous blood transfusion on IL-1, IL-6, TNF-α and liver function recovery in patients undergoing liver cancer surgery.

IF 2.8 4区医学

Discover. Oncology Pub Date : 2024-12-20 DOI: 10.1007/s12672-024-01660-3

Dongliang Yin, Ruirong Niu, Peilin Lu, Ruilong Yin, Zhiqiang Lin

{"title":"The effect of stored autologous blood transfusion on IL-1, IL-6, TNF-α and liver function recovery in patients undergoing liver cancer surgery.","authors":"Dongliang Yin, Ruirong Niu, Peilin Lu, Ruilong Yin, Zhiqiang Lin","doi":"10.1007/s12672-024-01660-3","DOIUrl":"https://doi.org/10.1007/s12672-024-01660-3","url":null,"abstract":"Purpose: This study aim is to evaluate the application of stored autologous blood transfusion in liver cancer surgery and explore its impact on postoperative changes in inflammatory factors and liver function recovery.Method: The study used a control group (CG) design and included 150 patients who underwent liver cancer surgery. While the observation group (OG) got autologous blood that had been preserved, the CG had a standard allogeneic blood transfusion. Examine the variations between the CG and the OG using the following measures: prior to, during, and following surgery contrast MELD score, blood routine indicators, pro-inflammatory cytokine levels.Result: MELD ratings, IL-1, IL-6, TNF-α levels, and preoperative blood routine indicators did not differ between the observation and CGs (p > 0.05). However, the blood routine indicators in the OG were lower than those in the CG on the first day following surgery (p < 0.05); seven days following surgery, there was no significant difference among the experiment participants (p > 0.05). In the meanwhile, the postoperative OG's levels of IL-1, IL-6, TNF-α, and HAF were lower than those of the CG (p < 0.05). The PVF of the OG was lower than the CG on the first day following surgery (p < 0.05), but on the seventh day following surgery, there was no discernible difference between the experiment's participants (p > 0.05).Conclusion: The research outcomes showcase that stored autologous blood transfusion can reduce the levels of inflammatory factors after surgery and promote the recovery of liver function;Research suggests important references for further understanding the application and mechanism of stored autologous blood transfusion, and provide a basis for personalized treatment and recovery of liver cancer patients undergoing surgery.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"15 1","pages":"815"},"PeriodicalIF":2.8,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ALKBH1: emerging biomarker and therapeutic target for cancer treatment.

IF 2.8 4区医学

Discover. Oncology Pub Date : 2024-12-20 DOI: 10.1007/s12672-024-01696-5

Ming Zhu Xiao, Jin Yin Fu, Le Tao Bo, Yi Dong Li, Zhong Wei Lin, Zhe Sheng Chen

引用次数: 0

Identifying therapeutic target for prostate cancer: exploring Diosmetin as a CYP inhibitor.

IF 2.8 4区医学

Discover. Oncology Pub Date : 2024-12-20 DOI: 10.1007/s12672-024-01711-9

Mohammad Habibur Rahman Molla, Mohammed Othman Aljahdali

{"title":"Identifying therapeutic target for prostate cancer: exploring Diosmetin as a CYP inhibitor.","authors":"Mohammad Habibur Rahman Molla, Mohammed Othman Aljahdali","doi":"10.1007/s12672-024-01711-9","DOIUrl":"https://doi.org/10.1007/s12672-024-01711-9","url":null,"abstract":"Prostate cancer is a prevalent and highly heterogeneous malignancy that affects men globally. Despite the availability of various treatment targets, Cytochrome P450 (CYP) enzymes have gained significant attention due to their crucial role in metabolizing both endogenous and exogenous compounds. This study explores Diosmetin as a potential CYP antagonist for treating prostate cancer. To evaluate Diosmetin's potential as a CYP antagonist, we employed a comprehensive in silico approach. Molecular docking was conducted using the Glide software to assess the binding affinity of Diosmetin with CYP enzymes, specifically CYP17A1 and CYP19A1, which are associated with prostate cancer. The druglike properties of Diosmetin were evaluated, focusing on its pharmacokinetic attributes. Additionally, Diosmetin's ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) characteristics were analyzed to determine its suitability as a therapeutic agent. Molecular dynamics (MD) simulations were performed using Desmond to assess the stability and persistence of Diosmetin binding with the CYP enzymes over a 200 ns simulation period. Molecular docking studies revealed robust binding affinities between Diosmetin and CYP17A1 (- 11.261 kcal/mol) and CYP19A1 (- 11.145 kcal/mol). Diosmetin demonstrated favorable pharmacokinetic properties and advantageous ADMET characteristics, including high bioavailability, good dispersion, and favorable metabolism. MD simulations indicated persistent binding interactions between Diosmetin and the CYP enzymes throughout the 200 ns simulation, reinforcing the reliability of these interactions. Pharmacoinformatics investigations provide valuable insights into the potential of Diosmetin as a promising lead compound for the development of novel drug candidates against prostate cancer. The strong binding affinity and favorable pharmacokinetic and ADMET profiles suggest that Diosmetin could be an effective CYP antagonist and warrants further investigation as a potential therapeutic agent for prostate cancer.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"15 1","pages":"814"},"PeriodicalIF":2.8,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The chemotactic response of Caenorhabditis elegans represents a promising tool for the early detection of cancer.

IF 2.8 4区医学

Discover. Oncology Pub Date : 2024-12-20 DOI: 10.1007/s12672-024-01721-7

Alžbeta Kaiglová, Patrícia Hockicková, Zuzana Bárdyová, Radka Reháková, Kamila Melnikov, Soňa Kucharíková

{"title":"The chemotactic response of Caenorhabditis elegans represents a promising tool for the early detection of cancer.","authors":"Alžbeta Kaiglová, Patrícia Hockicková, Zuzana Bárdyová, Radka Reháková, Kamila Melnikov, Soňa Kucharíková","doi":"10.1007/s12672-024-01721-7","DOIUrl":"https://doi.org/10.1007/s12672-024-01721-7","url":null,"abstract":"The nematode Caenorhabditis elegans, with its highly sensitive olfactory system, has emerged as a promising tool for testing chemotaxis. In the field of cancer diagnostics, there is a growing interest in the development of non-invasive screening methods for the detection of volatile organic compounds in a patient's urine. The objective of this study was to contribute to the existing body of knowledge by evaluating the ability of a Caenorhabditis elegans-based chemotaxis assay to discriminate between urine samples from healthy individuals and patients diagnosed with breast or colon cancer. Following synchronization of the developmental stages of C. elegans, nematodes were exposed to the urine of cancer patients and healthy individuals. Subsequently, chemotactic indices were calculated for each urine sample. Our results demonstrated a statistically significant difference in the chemotactic response of C. elegans to urine samples from cancer patients compared to healthy volunteers (p < 0.001). Furthermore, the test demonstrated promising diagnostic utility, with a sensitivity of 96%, a specificity of 62%, and a detection rate of 73% among patients with breast cancer and a sensitivity of 100%, a specificity of 62%, and a detection rate of 72% among those with colon cancer. Our findings expand on previous observations, confirming the remarkable sensitivity of C. elegans hermaphrodites to discriminating cancer-related volatile organic compounds in urine samples.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"15 1","pages":"817"},"PeriodicalIF":2.8,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0